Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Procept BioRobotics Believes Aquablation Could Dominate BPH Treatment…If It Gets Coverage

Executive Summary

Results of the WATER II trial confirm that Aquablation is a safe and effective treatment of benign prostate hyperplasia for large prostates, and manufacturer Procept BioRobotics is confident the procedure will eventually displace all other prostate resection techniques because it is easy for surgeons to learn.

Advertisement

Related Content

Procept's Aquablation BPH Therapy Gets Boost From UK NICE Guidance
Three Devices Gain Medicare Add-Ons, Including Boston Sci's New TAVR Protector
Medicare Bonus Payments: CMS Plans To End Three, But Considers Seven New-Tech Add-On Payments For FY 2019
Device Debut: Procept Biorobotics Expects To Make A Splash With AquaBeam

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT122813

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel